海(hai)(hai)默(mo)尼(ni)(ni)(ni)藥(yao)(yao)業股(gu)份有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)是一家(jia)從事藥(yao)(yao)品研發、生產、銷售及(ji)推(tui)廣服務的綜(zong)合性醫藥(yao)(yao)企業。公(gong)(gong)(gong)司(si)(si)注冊(ce)在拉薩(sa),旗(qi)下主(zhu)要子公(gong)(gong)(gong)司(si)(si)包括(kuo):重慶海(hai)(hai)默(mo)尼(ni)(ni)(ni)制藥(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)、西(xi)藏(zang)美迪信(xin)醫藥(yao)(yao)科技有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)、西(xi)藏(zang)凱昱醫藥(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)、海(hai)(hai)默(mo)尼(ni)(ni)(ni)(香港)貿易(yi)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si),以(yi)及(ji)臺灣(wan)海(hai)(hai)默(mo)尼(ni)(ni)(ni)藥(yao)(yao)業有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)、德國海(hai)(hai)默(mo)尼(ni)(ni)(ni)藥(yao)(yao)業有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)、瑞士海(hai)(hai)默(mo)尼(ni)(ni)(ni)藥(yao)(yao)業有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)和香港海(hai)(hai)默(mo)寧貿易(yi)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)4家(jia)二級子公(gong)(gong)(gong)司(si)(si)。
公司以“為您的(de)健康(kang)不懈努力”為使命,致力于放眼(yan)全(quan)球(qiu),立(li)足中國(guo),成(cheng)為值得信賴的(de)醫藥企業。通(tong)過實施(shi)“藥品(pin)并購”戰略,公司迅速(su)豐富產品(pin)管線,解決市場(chang)準(zhun)入(ru),實現規(gui)模銷(xiao)售(shou)(shou)(shou)。同時(shi)積極壯大(da)銷(xiao)售(shou)(shou)(shou)隊伍,建立(li)相應的(de)規(gui)章制度、業務(wu)流程,打造有效運營體系,增加銷(xiao)售(shou)(shou)(shou)覆蓋密度,提升銷(xiao)售(shou)(shou)(shou)能力,擴大(da)銷(xiao)售(shou)(shou)(shou)規(gui)模。
公(gong)司在建(jian)立起優秀的(de)(de)業(ye)務發展能力基礎上,在確(que)定的(de)(de)核(he)心疾病治療領域除并(bing)購(gou)國內(nei)已上市(shi)(shi)成熟產品以外,還(huan)積(ji)極布(bu)局并(bing)購(gou)國內(nei)未上市(shi)(shi)新(xin)產品、新(xin)技(ji)術,與不同層級(ji)的(de)(de)科研(yan)院所、CRO等(deng)機構開展廣泛合作,建(jian)立起多層次、多渠道(dao)的(de)(de)業(ye)務發展模式(shi)。通過(guo)對(dui)外并(bing)購(gou)、許可授權、委托(tuo)研(yan)發等(deng)方(fang)式(shi),打造開放式(shi)研(yan)發模式(shi),構建(jian)優異的(de)(de)產品管線建(jian)設能力。
公司積極提(ti)升技術(shu)轉(zhuan)移能(neng)力(li)和生產能(neng)力(li),全資子公司重慶海(hai)默尼已建成(cheng)年產超過1000萬(wan)盒固體制(zhi)劑的生產車間,覆蓋膠囊劑、片(pian)劑、顆粒劑等(deng)多(duo)種劑型,升級成(cheng)果轉(zhuan)化能(neng)力(li)。
目前,公(gong)司已基(ji)本形成了“自有藥(yao)(yao)品為(wei)主,代(dai)理藥(yao)(yao)品為(wei)輔”的(de)業務(wu)格局,建成了涵蓋藥(yao)(yao)品研(yan)發、生(sheng)產、銷售的(de)全產業鏈體系。未來(lai),公(gong)司將繼(ji)續通過開(kai)放式研(yan)發模式,持續豐富自有品種,擴大自主生(sheng)產能力,強化營銷網(wang)絡(luo),逐步發展成為(wei)聚焦(jiao)核心疾病(bing)治療領域、具備核心競(jing)爭力的(de)綜合性醫藥(yao)(yao)企(qi)業。